论文部分内容阅读
目的 :探讨乙型肝炎病毒 (HBV)携带者的治疗方法。方法 :应用左旋咪唑涂布剂联合潘生丁 ,乙肝疫苗治疗 HBV携带者中 HBe Ag、抗 HBc- Ig M、HBV- DNA均阳性者 80例 (原入组为 90例 ,后脱失 10例 ) ,治疗 组 12例 ,治疗 组 6 8例 ,并设对照组 90例 ,观察至 6～ 18个月。结果 :治疗 6个月时治疗 组 :HBe Ag、抗 HBc- Ig M、HBV- DNA阴转率5 8.33%、6 6 .6 7%、5 8.33% ;治疗 组分别为 38.2 4%、41.18%、41.18% ;对照组 HBe Ag阴转 2 .2 2 %。治疗 12个月时治疗 组 HBe Ag、抗 HBc- Ig M、HBV- DNA阴转分别累计为 83.33%、91.6 7%、83.33% ;治疗 组阴转分别累计达 47.0 6 %、6 3.2 4%、6 0 .2 9% ;对照组 HBe Ag阴转 5 .5 6 %。治疗 18个月时 HBe Ag、抗 HBc- Ig M、HBV- DNA阴转累计分别为 :治疗 组均为 10 0 % ;治疗 组为 5 4.41%、75 %、6 6 .18% ;对照组 HBe Ag阴转为 7.78% ,均有非常显著性差异。结论 :左旋咪唑涂布剂联合潘生丁、乙肝疫苗联合治疗 HBV携带者安全有效 ,用药方法简便 ,费用低廉 ,易于接受
Objective: To investigate the treatment of hepatitis B virus (HBV) carriers. Methods: 80 cases of HBe Ag, anti-HBc-Ig M and HBV-DNA positive were treated with levamisole coating combined with dipyridamole and hepatitis B vaccine in HBV carriers (90 in the original group and 10 in the later group) The treatment group of 12 cases, the treatment group of 68 cases, and the control group of 90 cases, observed until 6 to 18 months. Results: At the 6th month of treatment, HBe Ag, anti HBc-Ig M and HBV DNA negative conversion rates were 5 8.33%, 66.77% and 5 8.33% respectively. The treatment groups were 38.2%, 41.18% , 41.18% in the control group; HBe Ag in the control group turned to 2.2.2%. After treatment for 12 months, the HBe Ag, anti-HBc-Ig M and HBV-DNA negative conversion of the treatment group were 83.33%, 91.6 7% and 83.33% respectively. The negative conversion of the treatment group was 47.0 6% and 6 3.2 4% 60.29%; control group HBeAg negative 5.5%. HBeAg, anti-HBc-Ig M and HBV-DNA in 18 months after treatment were respectively: 100% in the treatment group, 5.41% in the treatment group, 75% in the treatment group and 6.6% in the control group Ag overcast to 7.78%, there is a very significant difference. Conclusion: Levamisole combined with dipyridamole and hepatitis B vaccine in the treatment of HBV carriers is safe and effective, the method is simple, inexpensive and easy to accept